Failure of ketanserin, a serotonin inhibitor, to prevent spontaneous or ergonovine-induced attacks of variant angina

L. A. Mata-Bourcart, D. D. Waters, A. Bouchard, D. D. Miller, P. Théroux

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Six patients hospitalized with active variant angina were treated for 3 days with the serotonin antagonist ketanserin after a 3 day control period on no medication. The number of variant angina episodes per patient per day was 1.52 ± 1.42 during the control period and 2.05 ± 2.30 during ketanserin therapy (p = NS). Ergonovine was administered in incremental doses of 0.0125 mg to 0.4 mg in the control period, during intravenous ketanserin administration and after 3 days of oral treatment. All 6 patients developed ST elevation during all 3 ergonovine tests. The ergonovine dose at which ST elevation developed was similar in each of the 3 periods. It is concluded that ketanserin is of no value in the treatment of variant angina and that both spontaneous and ergonovine-induced spasm in man are unlikely to be mediated by a serotonergic mechanism.

Original languageEnglish (US)
Pages (from-to)168-171
Number of pages4
JournalCanadian Journal of Cardiology
Volume1
Issue number3
StatePublished - Dec 4 1985
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Failure of ketanserin, a serotonin inhibitor, to prevent spontaneous or ergonovine-induced attacks of variant angina'. Together they form a unique fingerprint.

  • Cite this